Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism

Kyle S. McCommis, Brian N. Finck

Research output: Contribution to journalReview articlepeer-review

24 Scopus citations

Abstract

A hepatic comorbidity of metabolic syndrome, known as nonalcoholic fatty liver disease (NAFLD), is increasing in prevalence in conjunction with the pandemics of obesity and diabetes. The spectrum of NAFLD ranges from simple hepatic fat accumulation to a more severe disease termed nonalcoholic steatohepatitis (NASH), involving inflammation, hepatocyte death, and fibrosis. Importantly, NASH is linked to a much higher risk of cirrhosis, liver failure, and hepatocellular carcinoma, as well as an increased risk for nonhepatic malignancies and cardiovascular disease. Interest in the understanding of the disease processes and search for treatments for the spectrum of NAFLD-NASH has increased exponentially, but there are no approved pharmacologic therapies. In this review, we discuss the existing literature supporting insulin-sensitizing thiazolidinedione compounds as potential drug candidates for the treatment of NASH. In addition, we put these results into new context by summarizing recent studies suggesting these compounds alter mitochondrial metabolism by binding and inhibiting the mitochondrial pyruvate carrier.

Original languageEnglish
Pages (from-to)275-284
Number of pages10
JournalCMGH
Volume7
Issue number2
DOIs
StatePublished - 2019

Keywords

  • Mitochondria
  • Nonalcoholic Steatohepatitis
  • Pyruvate
  • Thiazolidinedione

Fingerprint

Dive into the research topics of 'Treating Hepatic Steatosis and Fibrosis by Modulating Mitochondrial Pyruvate Metabolism'. Together they form a unique fingerprint.

Cite this